Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

- Hofman, Michael S., Emmett, Louise, Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Sandhu, Shahneen, Redfern, AD, Macdonald, W, Guminski, A, Hsiao, E, Chua, W, Lin, P, Zhang, AY, Stockler, MR, Williams, SG, Martin, AJ, Iravani, Amir, Davis, ID, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group,, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D.

Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial

- Wegener, Eric, Sidhom, Mark, Arumugam, Sankar, Keats, Sarah, Brown, Simon, Glyde, Alan, Martin, Jarad M., Pryor, David, Bucci, Joseph, Yeoh, Kenway, Richardson, Matthew, Greer, Peter, Wilton, Lee, Gallagher, Sarah, Schmidt, Laurel

Prostate-specific antigen response to androgen deprivation therapy in the neoadjuvant setting for high-risk prostate adenocarcinoma (PIRANHA): Pooled analysis of two randomized clinical trials

- Nikitas, John, Ong, Wee Loon, Valle, Luca, McGuire, Sean E., Spratt, Daniel E., Souhami, Luis, Roy, Soumyajit, Martin, Jarad M., Joseph, David, Nabid, Abdenour, Kishan, Amar U., Carrier, Nathalie, Romero, Tahmineh, Millar, Jeremy, Steinberg, Michael L., Rettig, Matthew B., Boutros, Paul C., Reiter, Robert, Nickols, Nicholas G.

Benefits and harms of prostate specific antigen testing according to Australian guidelines

- Caruana, Michael, Gulati, Roman, Smith, David P., O'Connell, Dianne L., Canfell, Karen, Etzioni, Ruth, Barratt, Alexandra, Armstrong, Bruce K., Chiam, Karen, Nair-Shalliker, Visalini, Luo, Qingwei, Bang, Albert, Grogan, Paul

Challenges and opportunities for implementing hypofractionated radiotherapy in Africa: lessons from the HypoAfrica clinical trial

- Olatunji, Elizabeth, Swanson, William, Joseph, Adedayo O., Lehmann, Joerg, Li, Heng, Mallum, Abba, Mkhize, Thokozani, Ngoma, Twalib Athumani, Studen, Andrej, Wijesooriya, Krishni, Incrocci, Luca, Ngwa, Wilfred, Patel, Saloni, Adeneye, Samuel Olaolu, Aina-Tofolari, Funimilayo, Avery, Stephen, Kisukari, Jumaa Dachi, Graef, Katy, Huq, Saiful, Jeraj, Robert

Clinical target volume delineation quality assurance for MRI-guided prostate radiotherapy using deep learning with uncertainty estimation

- Min, Hang, Dowling, Jason, Chlap, Phillip, de Leon, Jeremiah, Berry, Megan, Pryor, David, Greer, Peter, Vinod, Shalini K., Holloway, Lois, Jameson, Michael G., Cloak, Kirrily, Faustino, Joselle, Sidhom, Mark, Martin, Jarad, Cardoso, Michael, Ebert, Martin A., Haworth, Annette

Design of drug delivery system based on stimuli-responsive mesoporous silica nanoparticles with core-shell structure for prostate cancer

- Mohanan, Shan

Determination of acceptable Hounsfield units uncertainties via a sensitivity analysis for an accurate dose calculation in the context of prostate MRI-only radiotherapy

- Chourak, Hilda, Barateau, Anaïs, Greer, Peter, Lafond, Caroline, Nunes, Jean-Claude, de Crevoisier, Renaud, Dowling, Jason, Acosta, Oscar

Patient-Reported Urinary and Bowel Quality of Life Outcomes Following External Beam Radiotherapy with or without High-Dose-Rate Brachytherapy Boost: Post-Hoc Analyses of TROG 03.04 (RADAR)

- Ong, W. L., Nikitas, J., Zaorsky, N. G., Spratt, D. E., Romero, T., Kishan, A. U., Joseph, D. J., Steigler, A., Denham, J. W., Millar, J. L., Valle, L., Steinberg, M. L., Ma, T. M., Chang, A. J.

Validation of prediction models for radiation-induced late rectal bleeding: Evidence from a large pooled population of prostate cancer patients

- Cicchetti, Alessandro, Fiorino, Claudio, Esposti, Claudio Degli, Gabriele, Pietro, Munoz, Fernando, Avuzzi, Barbara, Valdagni, Riccardo, Rancati, Tiziana, Ebert, Martin A., Iacovacci, Jacopo, Kennedy, Angel, Joseph, David J., Denham, James W., Vavassori, Vittorio, Fellin, Gianni, Cozzarini, Cesare

Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech

- Wegener, Eric, Samuels, Justin, Sidhom, Mark, Trada, Yunvik, Sridharan, Swetha, Dickson, Samual, McLeod, Nichola, Martin, Jarad M.

A statistical, voxelised model of prostate cancer for biologically optimised radiotherapy

- Finnegan, Robert N., Reynolds, Hayley M., Ebert, Martin A., Sun, Yu, Holloway, Lois, Sykes, Jonathan R., Dowling, Jason, Mitchell, Catherine, Williams, Scott G., Murphy, Declan G., Haworth, Annette

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis

- Kishan, Amar U., Sun, Yilun, Armstrong, John G., Nabid, Abdenour, Carrier, Nahtalie, Souhami, Luis, Dunne, Mary T., Efstathiou, Jason A., Sandler, Howard M., Guerrero, Araceli, Joseph, David, Maingon, Philippe, Hartman, Holly, de Reijke, Theo M., Maldonado, X, Ma, TM, Romero, T, Wang, X, Rettig, MB, Reiter, RE, Zaorsky, NG, Steinberg, ML, Nickols, NG, Pisansky, Thomas M., Jia, AY, Garcia, JA, Spratt, DE, Bolla, Michel, Neven, Anouk, Steigler, Allison, Denham, James W., Feng, Felix Y., Zapatero, Almudena

Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia

- Luo, Qingwei, Yu, Xue Qin, Kahn, Clare, Egger, Sam, Patel, Manish I., Grogan, Paul B., Caruana, Michael, Canfell, Karen, Smith, David P., O'Connell, Dianne L.

Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial – PROFIT

- Zhou, K., Renouf, M., Catton, C., Bellanger, M., Supiot, S., Perrocheau, G., Magné, N., Latorzeff, I., Pommier, P., Créhange, G., Paumier, A., Bera, G., Martin, J.

Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

- Kishan, Amar U., Steigler, Alison, Pilar, Avinash, Reddy, Chandana, Wedde, Trude B., Lilleby, Wolfgang A., Fiano, Ryan, Merrick, Gregory S., Stock, Richard G., Demanes, D. Jeffrey, Moran, Brian J., Tran, Phuoc T., Denham, James W., Martin, S, Martinez-Monge, R, Krauss, DJ, Abu-Isa, EI, Pisansky, TM, Choo, CR, Song, DY, Greco, S, Deville, C, McNutt, T, Zapatero, Almudena, DeWeese, TL, Ross, AE, Ciezki, JP, Tilki, D, Karnes, RJ, Tosoian, JJ, Nickols, NG, Bhat, P, Shabsovich, D, Juarez, JE, Guerrero, Araceli, Jiang, T, Ma, TM, Xiang, M, Philipson, R, Chang, A, Kupelian, PA, Rettig, MB, Feng, FY, Berlin, A, Tward, JD, Joseph, David, Davis, BJ, Reiter, RE, Steinberg, ML, Elashoff, D, Boutros, PC, Horwitz, EM, Tendulkar, RD, Spratt, DE, Romero, T, Maldonado, Xavier, Wong, Jessica K., Stish, Bradley J., Dess, Robert T.

Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)

- Ma, Ting Martin, Chu, Fang-I, Bolla, Michel, de Reijke, Theo M., Maingon, Philippe, Neven, Anouk, Denham, James, Steigler, Allison, Joseph, David J., Nabid, Abdenour, Souhami, Luis, Carrier, Nathalie, Sandler, Howard, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris J., Sydes, Matthew R., Dearnaley, David P., Tree, Alison C., Syndikus, Isabel, Hall, Emma, Cruickshank, Clare, Malone, Shawn, Feng, Felix Y., Roy, Soumyajit, Sun, Yilun, Zaorsky, Nicholas G., Nickols, Nicholas G., Reiter, Robert E., Rettig, Matthew B., Steinberg, Michael L., Reddy, Vishruth K., Xiang, Michael, Romero, Tahmineh, Efstathiou, Jason A., Spratt, Daniel E., Kishan, Amar U., Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators,, Jones, Christopher U., Roach, Mack, Rosenthal, Seth A., Pisansky, Thomas, Michalski, Jeff M.

Smart drug delivery system based on core-shell silica nanomaterials for prostate cancer

- Tiburcius, Steffi

Triple Surfactant Assisted Synthesis of Novel Core-Shell Mesoporous Silica Nanoparticles with High Surface Area for Drug Delivery for Prostate Cancer

- Tiburcius, Steffi, Krishnan, Kannan, Patel, Vaishwik, Netherton, Jacob, Sathish, C. I., Weidenhofer, Judith, Yang, Jae-Hun, Verrills, Nicole M., Karakoti, Ajay, Vinu, Ajayan

[Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

- Hofman, Michael S., Emmett, Louise, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Sandhu, Shahneen, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A., Williams, Scott G., Iravani, Amir, Martin, Andrew J., Davis, Ian D., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan